J Cancer 2017; 8(19):3945-3951. doi:10.7150/jca.22162

Research Paper

Fuzi Enhances Anti-Tumor Efficacy of Radiotherapy on Lung Cancer

Qi Zhang1, Xue Chen1, Youjun Luo1, Huaping Ren2, Tiankui Qiao1✉

1. Department of Oncology, Jinshan Hospital, Fudan University, Shanghai 201508, China;
2. Department of Chinese Medicine, Jinshan Hospital, Fudan University, Shanghai 201508, China.


In traditional Chinese medicine, Fuzi is widely used as an antitumor agent or an adjuvant medication combined with radiotherapy and chemotherapy, but its mechanism remains unclear. In this study, we investigated anti-tumor and immunoregulation efficacy of Fuzi combined with radiotherapy in mice with Lewis lung cancer (LLC). We found that Fuzi combined with radiotherapy significantly inhibited the growth of LLC, promoted the apoptosis of cancer cells, and prolonged the survival of mice with LLC. Mechanistically, we found that Fuzi decreased the proportion of Treg cells, reduced serum levels of cytokines such as interleukin (IL)-10 and transforming growth factor (TGF)-β, and downregulated the expression of programmed death ligand-1 in mice with LLC subjected to radiotherapy. This study suggests that Fuzi has immunomodulation function to act as radiosensitizer and improve radiotherapy against lung cancer.

Keywords: Radiotherapy, Fuzi, TGF-β, PD-L1, Treg cells, Lung cancer.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Zhang Q, Chen X, Luo Y, Ren H, Qiao T. Fuzi Enhances Anti-Tumor Efficacy of Radiotherapy on Lung Cancer. J Cancer 2017; 8(19):3945-3951. doi:10.7150/jca.22162. Available from http://www.jcancer.org/v08p3945.htm